Dr. Shivaani Kummar, MD
Claim this profileOregon Health and Science University
Studies Solid Tumors
Studies Colorectal Cancer
12 reported clinical trials
19 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
RET positive
2Colorectal Cancer
Stage IV
Stage III
RET positive
Affiliated Hospitals
Clinical Trials Shivaani Kummar, MD is currently running
Axatilimab + Retifanlimab + Paclitaxel
for Cancer
This phase I/II trial tests the safety, side effects, and effectiveness of axatilimab in combination with retifanlimab and paclitaxel for the treatment of patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Axatilimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Giving axatilimab in combination with retifanlimab and paclitaxel may be safe, tolerable and/or effective in treating patients with advanced or metastatic solid tumors.
Recruiting1 award Phase 1 & 2
PC14586
for Solid Tumors
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Recruiting1 award Phase 1 & 25 criteria
More about Shivaani Kummar, MD
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Shivaani Kummar, MD has experience with
- Pembrolizumab
- ASTX029
- Zenocutuzumab (MCLA-128)
- ORIC-101
- Nab-paclitaxel
- PD(L)-1 Inhibitor
Breakdown of trials Shivaani Kummar, MD has run
Solid Tumors
Tumors
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shivaani Kummar, MD specialize in?
Shivaani Kummar, MD focuses on Solid Tumors and Colorectal Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Shivaani Kummar, MD currently recruiting for clinical trials?
Yes, Shivaani Kummar, MD is currently recruiting for 7 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Shivaani Kummar, MD has studied deeply?
Yes, Shivaani Kummar, MD has studied treatments such as Pembrolizumab, ASTX029, Zenocutuzumab (MCLA-128).
What is the best way to schedule an appointment with Shivaani Kummar, MD?
Apply for one of the trials that Shivaani Kummar, MD is conducting.
What is the office address of Shivaani Kummar, MD?
The office of Shivaani Kummar, MD is located at: Oregon Health and Science University, Portland, Oregon 97239 United States. This is the address for their practice at the Oregon Health and Science University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.